Drug Profile


Alternative Names: CAT-1004; Docosahexaenoic acid-sodium salicylate conjugate; Sodium salicylate-docosahexaenoic acid conjugate

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Developer Catabasis Pharmaceuticals; Sarepta Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Docosahexaenoic acids; Non-opioid analgesics; Salicylates; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 04 Oct 2017 Updated efficacy data from the phase I/II MoveDMD trial in Duchenne Muscular Dystrophy released by Catabasis Pharmaceuticals
  • 04 Oct 2017 Catabasis plans a global phase III trial for Duchenne Muscular Dystrophy in the first half of 2018
  • 25 Apr 2017 Updated efficacy data from the phase I/II MoveDMD trial (Part B) in Duchenne Muscular Dystrophy reported at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top